# reload+after+2024-01-21 17:44:24.422769
address1§11682 El Camino Real
address2§Suite 300
city§San Diego
state§CA
zip§92130
country§United States
phone§858 997 2400
website§https://www.dmkpharmaceuticals.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.
fullTimeEmployees§11
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Seth Abraham Cohen', 'age': 60, 'title': 'Chief Financial Officer', 'yearBorn': 1963, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John W. Dorbin Jr.', 'age': 52, 'title': 'General Counsel Corporate Secretary', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.256
priceToSalesTrailing12Months§1.8991748
currency§USD
dateShortInterest§1702598400
forwardEps§-4.39
exchange§NCM
quoteType§EQUITY
shortName§DMK Pharmaceuticals Corporation
longName§DMK Pharmaceuticals Corporation
firstTradeDateEpochUtc§808407000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§021cbf74-ddb5-3b5d-8c89-80eb8f2ee700
gmtOffSetMilliseconds§-18000000
targetHighPrice§1.5
targetLowPrice§1.5
targetMeanPrice§1.5
targetMedianPrice§1.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§0.495
grossMargins§-0.37297
ebitdaMargins§0.0
trailingPegRatio§None
